2018 Symposium on “Human Pluripotent Stem Cell-based Precision Medicine and Therapies for Heart Diseases: From Concepts to Realities”

Session I: Cell-Based Cardiac Therapies

Gene therapy & genome editing for acquired and experimental heart failure

Roger Hajjar
Director, Cardiovascular Research Center
Arthur & Janet C. Ross Professor of Medicine, Icahn School of Medicine at Mount Sinai

The potential of human induced pluripotent stem cells to model and to treat congenital heart disease

Yiu-fai Cheung
Bryan Lin Professor in Paediatric Cardiology
Clinical Professor, Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong

Development of banking and testing protocols for GMP hiPSC

Jo Mountford
Head of Cellular Therapeutics, Tissues Cells and Advanced Therapies, Scottish National Blood Transfusion Service
Hon. Associate Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow

Predicting individual arrhythmogenic risk at the individual level using hiPSC

Jean-Sébastien Hulot
Team Leader, Clinical & Translational Investigation Center, Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest) Paris Cardiovascular Research Center PARCC / INSERM

Session II: Tissue Engineering and Drug Discovery

Engineering cardiac tissue and development

Peter Zandstra
Director, School of Biomedical Engineering, The University of British Columbia

A tissue-engineered scale model of the heart ventricle

Luke MacQueen/Kit Parker
Postdoctoral Fellow / Professor, Bioengineering in the Wyss Institute, Harvard University

Small molecule drug discovery, transitioning from industry to academia: SERCA2a SUMO activators for heart failure

Robert DeVita
Director of Medicinal Chemistry, Drug Discovery Institute
Professor, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai

Session III: Drug and Therapeutics Safety and Discovery in Industry

Stem cell cardiomyocytes in drug discovery and development – are we there yet?

Bernard Fermini
Co-Chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration

New challenges in safety pharmacology

Sonja Stoelzle-Feix
Director Scientific Affairs at Nanion Technologies
Co-chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration

Toward a precision medicine approach to drug screening using Novoheart’s hPSC-based MyHeart^TM Platform

Kevin Costa
Co-founder and Chief Scientific Officer, Novoheart

Collaborating to create engineered human tissues using 3D bioprinting technology

Tamer Mohamed
President and Chief Executive Officer, Aspect Biosystems

Session IV: Commercializing Regenerative Medicine and Therapeutics

Scale-up of pluripotent stem cell production to enable translation and commercialization

Emily Titus
Vice President, Technology Advancement, Centre for Commercialization of Regenerative Medicine (CCRM)

Where is Hong Kong in developing precision medicine?

Sabrina Chan
Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry